ストックスクリーナーアプリを入手
2.38
12.26%
0.26
アフターアワーズ：
2.39
0.01
+0.42%
前日終値:
$2.12
開ける：
$2.15
24時間の取引高:
11.98M
Relative Volume:
0.74
時価総額：
$297.40M
収益：
-
当期純損益:
$-112.46M
株価収益率:
-1.4512
EPS:
-1.64
ネットキャッシュフロー:
$-99.89M
1週間 パフォーマンス:
+3.03%
1か月 パフォーマンス:
+1,054%
6か月 パフォーマンス:
+78.95%
1年 パフォーマンス:
+138.81%
1日の値動き範囲:
$2.1493
$2.65
1週間の範囲:
$1.92
$2.84
52週間の値動き範囲:
$0.1311
$3.29
Vor Biopharma Inc Stock (VOR) Company Profile
VOR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
2.38 | 288.66M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-30 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2022-07-26 | 開始されました | Wedbush | Outperform |
| 2022-04-27 | 開始されました | Goldman | Neutral |
| 2021-12-17 | 開始されました | H.C. Wainwright | Buy |
| 2021-12-03 | 開始されました | Robert W. Baird | Outperform |
| 2021-12-02 | 開始されました | Oppenheimer | Outperform |
| 2021-10-19 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-03-25 | 開始されました | B. Riley Securities | Buy |
| 2021-03-03 | 開始されました | Barclays | Overweight |
| 2021-03-03 | 開始されました | Evercore ISI | Outperform |
| 2021-03-02 | 開始されました | Goldman | Sell |
| 2021-03-02 | 開始されました | Stifel | Buy |
すべてを表示
Vor Biopharma Inc (VOR) 最新ニュース
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer - Yahoo Finance
Vor Biopharma Faces Crucial Market Shifts Amid Latest Developments - StocksToTrade
Vor Biopharma Stock Faces Volatile Week Amid Mixed Financial Reports - timothysykes.com
Vor Biopharma Inc. shares rise 2.00% premarket after Bonesupport CEO predicts strong growth. - AInvest
How Vor Biopharma Inc. stock performs during market volatilitySafe Entry High Exit Alerts - Newser
What makes Vor Biopharma Inc. stock price move sharplySteady Profit Stock Forecasts - Newser
Why Vor Biopharma Inc. stock attracts strong analyst attentionBreakout Confirmation Tool - Newser
Vor Biopharma Stock’s Rollercoaster: Time to Buy? - StocksToTrade
VOR’s 2025 Market Dance: Up 174.66% – Time to Invest? - investchronicle.com
Vor Biopharma Explodes 22% – What’s Fueling the Surge? - AInvest
Vor Biopharma Names Sandy Mahatme as CFO, Chief Business Officer - MarketScreener
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer - The Manila Times
Vor Bio Strengthens Leadership: Top Biotech Executive Who Raised $6B Joins as New CFO/CBO - Stock Titan
Vor Biopharma Sees Unusually High Options Volume (NYSE:VOR) - Defense World
Vor Biopharma Shares Soar 23.22% on Analyst Upgrades - AInvest
Vor Biopharma: Not So Sure About This Surge, And Do Mind The Warrants - Seeking Alpha
VOR’s Unexpected Surge: What’s Driving the Spike? - timothysykes.com
VOR Biopharma Inc. Faces Uncertain Future Amid Recent Developments - StocksToTrade
Vor Biopharma Soars 19.1% on Analyst Upgrade - AInvest
Vor Biopharma Stock Skyrockets: What’s Next? - StocksToTrade
Vor Biopharma shares surge 28.01% intraday after licensing telitacicept for autoimmune diseases and raising $1.75B in private funding. - AInvest
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Vor Biopharma (NASDAQ:VOR) Stock Rating Upgraded by HC Wainwright - Defense World
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Massive CEO Stock Grant: Vor Bio Awards 83M Shares to New Chief Executive at $0.89 - Stock Titan
Vor Biopharma (NYSE:VOR) Rating Increased to Buy at HC Wainwright - Defense World
Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market - Benzinga
Vor Biopharma (VOR) Receives Upgrade to Buy Rating by HC Wainwri - GuruFocus
Vor Biopharma stock rating upgraded to Buy by H.C. Wainwright on telitacicept deal - Investing.com
Vor Biopharma (VOR) Receives Upgrade to Buy Rating by HC Wainwright & Co. | VOR Stock News - GuruFocus
Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why - Yahoo Finance
VOR SEC FilingsVor Biopharma Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Vor Biopharma's Mysterious 10% Spike: What Drives a Stock Without Technical Triggers? - AInvest
Vor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune Therapy - MSN
After axing 95% workforce, Vor bets $4B+ on Remegen’s telitacicept - BioWorld MedTech
Vor Biopharma stock soars after licensing deal for autoimmune therapy By Investing.com - Investing.com Canada
PureTech's Vor Bio Lands $4B Autoimmune Drug Deal, Names New CEO, Raises $175M - Stock Titan
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset - Yahoo Finance
Vor Biopharma Stock Rises 1.72% Amid Mixed Analyst Forecasts - AInvest
Short Interest in Vor Biopharma Inc. (NYSE:VOR) Increases By 51.8% - Defense World
Vor Biopharma Inc (VOR) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Market Insights: Triller Group Inc (ILLR)’s Notable Gain of 1.91, Closing at 0.69 - DWinneX
Vor Biopharma Inc (VOR) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Data-Based Insights About Vor Biopharma Inc (VOR) - Stocksregister
Vor Biopharma Inc. (NYSE:VOR) Given Average Recommendation of “Hold” by Analysts - Defense World
Northern Trust Corp Acquires 44,252 Shares of Vor Biopharma Inc. (NYSE:VOR) - Defense World
Cambridge biotech company researching blood cancers to close, lay off 155 - Yahoo Finance
Vor Biopharma Inc (NASDAQ: VOR) Stock Forecast: Could Pass $6 In A Year - Stocksregister
Vor Biopharma draws downgrades on strategic review - MSN
Vor Biopharma’s SWOT analysis: biotech firm halts programs, explores options By Investing.com - Investing.com South Africa
Vor Biopharma’s SWOT analysis: biotech firm halts programs, explores options - Investing.com
Vor Biopharma Inc (VOR) 財務データ
収益
当期純利益
現金流量
EPS
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):